Ho-Sook Kim

Ho-Sook Kim

Auto-generated profile, based on publicly available information

Ho-Sook Kim

Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan 47392, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
WKWoo-Ju Kim
Woo-Ju Kim
HKHo-Sook Kim
Ho-Sook Kim
Kim WJ, et al. Transl Clin Pharmacol. 2024 Mar;32(1):1-17. https://doi.org/10.12793/tcp.2024.32.e5

1 January 2020 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
WKWoo-Young Kim
Woo-Young Kim
HKHo-Sook Kim
Ho-Sook Kim
MOMinkyung Oh
Minkyung Oh
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
Kim WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e6. /Synapse/10.12793/tcp.2020.28.e6

28 February 2017 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
DKDong-Jin Kim
Dong-Jin Kim
HKHo-Sook Kim
Ho-Sook Kim
MOMinkyung Oh
Minkyung Oh
EKEun-Young Kim
Eun-Young Kim
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin

1 January 2019 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
EKEun-Young Kim
Eun-Young Kim
MKMi-Yeong Kim
Mi-Yeong Kim
CPChan Sun Park
Chan Sun Park
JCJae-Hyeog Choi
Jae-Hyeog Choi
JGJong-Lyul Ghim
Jong-Lyul Ghim
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
Antiepileptic drugs (AEDs) can induce severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. We performed HLA genotyping and lymphocyte activation tests (LATs) for five AED-induced SCAR patients (three males and two females; aged 40-66 years old). Three patients were treated with carbamazepine (CBZ) for pain control, one was treated with phenytoin (PHT) for seizure prevention, and one was treated with valproic acid (VPA) for seizure prevention. One patient was diagnosed with CBZ-induced DRESS syndrome and the remaining patients were diagnosed with SJS. All patients recovered from SCARs after stopping suspicious drugs and supportive care. LATs were conducted to confirm the culprit drug responsible for inducing SCARs; and LAT results were positive for the suspected culprit drugs, in all except in one case. HLA-A, -B, and -C alleles were determined using PCR-sequence-based typing method. The common alleles of HLA were -A*02:01, -B*51:01, and -C*03:04 which were carried by three patients (60%) for each allele. The patient with CBZ-induced DRESS syndrome carried the HLA-A* 31:01 allele. One patient with CBZ-induced SJS and one patient with VPA-induced SJS carried the HLA-B*15:11 allele. No patients carried the HLA-B*15:02 allele, which is a known risk allele of AED-induced SCARs. Further investigation of the three common alleles found in the five AED-induced SCARs patients is needed. We demonstrated the usefulness of LAT for confirming the culprit drug.

1 November 2014 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
HKHo-Sook Kim
Ho-Sook Kim
MOMinkyung Oh
Minkyung Oh
EKEun Ji Kim
Eun Ji Kim
GSGeun Seog Song
Geun Seog Song
JGJong-Lyul Ghim
Jong-Lyul Ghim
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
The objective of this study was to evaluate the effects of voglibose on the pharmacokinetics of metformin. A randomized, open-label, two-way crossover study with a 7-day washout period was conducted. All subjects were given an oral dose of metformin with or without voglibose 3 x daily for 7 days. Plasma concentrations of metformin on day 7 were measured using high performance liquid chromatography (HPLC) with UV detection for pharmacokinetic assessment Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety. 22 subjects completed the study. The geometric mean ratios for C(ss,max) of metformin (metformin plus voglibose vs. metformin only) were 0.98 (90% CI, 0.92 - 1.05; p > 0.05) and for AUC-τ, the ratio was 0.99 (90% CI, 0.92 - 1.06; p > 0.05). There were no significant differences in adverse drug reactions between metformin with and without voglibose. However, the incidence of adverse events was higher in period 1 than in period 2 (16 cases vs. 1 case, p < 0.001). Co-administration of metformin and voglibose had no statistically or clinically significant effects on the pharmacokinetics of metformin in healthy subjects. The pharmacodynamic interaction study to evaluate the effect of metformin on the pharmacodynamics of voglibose is in progress.

1 February 2015 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Open access
HCHyang-Ki Choi
Hyang-Ki Choi
MOMinkyung Oh
Minkyung Oh
EKEun Ji Kim
Eun Ji Kim
GSGeun Seog Song
Geun Seog Song
JGJong-Lyul Ghim
Jong-Lyul Ghim
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
The aim of this study was to compare the pharmacokinetic characteristics of metformin between a fixed-dose combination (FDC) of voglibose/metformin and co-administered individual voglibose and metformin tablets in healthy Korean volunteers under fasting conditions. A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 7-day wash-out period was conducted. Plasma samples were collected for up to 24 hours and were analyzed for metformin using a validated liquid chromatography tandem mass-spectrometry (LC/MS). A non-compartmental method was used to calculate the pharmacokinetic parameters. Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety. In total, 28 subjects completed the study. The geometric mean ratio (GMR) and the 90% confidence interval (CIs) of Cmax and AUC0–t of metformin were 102.4 (94.5 – 111.0) and 107.1 (100.1 – 114.7), respectively. In total, 7 adverse drug reactions occurred in 4 subjects during the study; of these, 3 cases were from 3 subjects in the test treatment group, and 4 cases were from 3 subjects in the reference treatment group. All adverse drug reactions had been reported previously, and all subjects recovered fully without any sequelae. In conclusion, the pharmacokinetic profiles of metformin in two different study treatments, a voglibose/metformin FDC vs. the coadministration of the individual formulations, met the regulatory criteria for bioequivalence in healthy Korean subjects under fasting conditions. There was no significant difference in safety profiles between the two treatments.